Japan gave “emergency use” approval to the drug developed by the American pharmaceutical company Merck against COVID-19.
The Ministry of Health of Japan has given domestic use permission to the drug “Molnupiravir” to be used orally against COVID-19.
Accordingly, the way was opened for patients aged 18 years and older with mild symptoms to use the drug twice a day for 5 days.
Health Minister Goto Shigeyuki announced that the shipment of the drug to health institutions across the country will begin at the beginning of the week.
The Japanese government had previously agreed with the American company for the supply of 1.6 million doses of “Molnupiravir” drug.
Merck company applied to the ministry earlier this month for the emergency use approval of the drug it developed against COVID-19.
The drug, which was first approved by England, was also approved in the USA within a week.
Merck reported that Molnupiravir reduced the risk of hospitalization and death by 50 percent in newly infected individuals.